These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 6763540)

  • 1. Cyclosporin A as a tool for experimental and clinical transplantation.
    Tutschka PJ
    Biomed Pharmacother; 1982; 36(8-9):341-4. PubMed ID: 6763540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
    Hess AD
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cyclosporin A--a new immunosuppressive drug].
    Towpik E; Araujo JL; Kupiec-Wegliński J; Tilney NL
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1735-9. PubMed ID: 6395123
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of cyclosporin A on experimental graft-versus-host disease in rodents.
    van Bekkum DW; Knaan S; Zurcher C
    Transplant Proc; 1980 Jun; 12(2):278-82. PubMed ID: 6994295
    [No Abstract]   [Full Text] [Related]  

  • 6. Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome.
    Blazar BR; Taylor PA; Snover DC; Sehgal SN; Vallera DA
    J Immunol; 1993 Nov; 151(10):5726-41. PubMed ID: 8228258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A and the immune response to transplantation antigens.
    Hess AD
    Lymphokine Res; 1982; 1(2):23-7. PubMed ID: 6239956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin in bone marrow transplantation.
    Atkinson K
    Bone Marrow Transplant; 1987 Feb; 1(3):265-70. PubMed ID: 3332137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Composite vascularized skin/bone transplantation models for bone marrow-based tolerance studies.
    Ozmen S; Ulusal BG; Ulusal AE; Izycki D; Siemionow M
    Ann Plast Surg; 2006 Mar; 56(3):295-300. PubMed ID: 16508361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of the acute graft versus host skin reaction with cyclosporin and PUVA].
    Read D; Piérad GE; de la Brassinne M; Bury J
    Ann Dermatol Venereol; 1988; 115(4):427-31. PubMed ID: 3046456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin-A prophylactic treatment of graft-versus-host disease in human allogeneic bone marrow transplantation: preliminary results.
    Gluckman E; Arcese W; Devergie A; Boiron M
    Transplant Proc; 1981 Mar; 13(1 Pt 1):368-70. PubMed ID: 7022855
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of cyclosporin A in allogeneic bone marrow transplantation in the rat.
    Tutschka PJ; Beschorner WE; Allison AC; Burns WH; Santos GW
    Nature; 1979 Jul; 280(5718):148-51. PubMed ID: 45208
    [No Abstract]   [Full Text] [Related]  

  • 14. [New immunosuppressive agents].
    Socié G; Thervet E
    Pathol Biol (Paris); 1999 Oct; 47(8):827-35. PubMed ID: 10573703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin A.
    Morris PJ
    Transplantation; 1981 Nov; 32(5):349-54. PubMed ID: 6460358
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclosporin-A: effect on marrow engraftment and graft-versus-host disease in dogs.
    Deeg HJ; Storb R; Weiden PL; Graham T; Atkinson K; Thomas ED
    Transplant Proc; 1981 Mar; 13(1 Pt 1):402-4. PubMed ID: 7022862
    [No Abstract]   [Full Text] [Related]  

  • 17. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation.
    Truitt RL; Johnson BD; Hanke C; Talib S; Hearst JE
    J Immunol; 1999 Nov; 163(9):5145-56. PubMed ID: 10528221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free bone graft attenuates acute rejection and in combination with cyclosporin a leads to indefinite cardiac allograft survival.
    Wang H; Ge W; Arp J; Zassoko R; Liu W; Ichim TE; Jiang J; Jevnikar AM; Garcia B
    J Immunol; 2009 May; 182(10):5970-81. PubMed ID: 19414748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
    Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
    Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.